HUE033186T2 - Az intraokuláris nyomás csökkentése intrakamerális bimatoproszt implantátumokkal - Google Patents

Az intraokuláris nyomás csökkentése intrakamerális bimatoproszt implantátumokkal Download PDF

Info

Publication number
HUE033186T2
HUE033186T2 HUE14194703A HUE14194703A HUE033186T2 HU E033186 T2 HUE033186 T2 HU E033186T2 HU E14194703 A HUE14194703 A HU E14194703A HU E14194703 A HUE14194703 A HU E14194703A HU E033186 T2 HUE033186 T2 HU E033186T2
Authority
HU
Hungary
Prior art keywords
implant
eye
prostaglandin
implants
radical
Prior art date
Application number
HUE14194703A
Other languages
English (en)
Inventor
Patrick M Hughes
Michael R Robinson
James A Burke
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HUE033186T2 publication Critical patent/HUE033186T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (2)

  1. Az íptraokytárti: nyomás csökkentése hArakamerálls blm alaprészt i m pia nlity mokka I Igénypontok I* Kgy prosziaglandin a megnővekedotl iotraolutirls nyomás (IÖP; Infraoetflir pressure) kezelésében való haszniiiira, araeipwk serin egy fesologlailai lebontható IntraoMáris irnplarááfümit tislpzneiégy olyan pÉiiens stemébi:, aki az említett kezesre szorul, ahol: az implantátam egy prosztaglanduit tartalmaz az impfántátum 1§«á§ tömeg%-ának megfeleli mennyiségben, a prosziaglandin egy biológiailag lebontható polimer mátrixhoz iámul, amely olyan mennyiségben bocsátja ki a prosztaglendlnij: amely ihalikony a megnóvekeial ΙΟP tünetének megelőzésére vagy csökkentésére; és az Imptarvtáturn a szemkamrábs kerül 6:00 óm helyseiben, hogy tágítsa a izem kiáramlási csatornáit a Schfemm-csatomábői kiindulva, és ezáltal tél összekeverje a prosztaglandint az egész elülső szegmensben a korwekdős áramok révén i. Az 1. igénypont szerinti használatra való prosztaglandln, ahol az említett ímpíantáturn a szemkamrába kerül a 6:00 órai helyzetben, hogy kitágítsa az episzkleráils és konjunkfiváiis vénás plexus erest, fk Az 1. Igénypont szerinti használatra való prosztaglandln, ahol az ímpíantáturn a 6:00 órai helyzetbe kerül a szem elülső kamrájában.
  2. 4,, Az i, igénypont szerinti használatra való prosztagiáhdin, ahol az Implantáturn a 8:00 órai helyzetbe kerül Mögibéh. % Az 1. igénypont szerinti használatra való prosziaglandin, ahol az impiantátumot egy olyan okpláriaszerelviny fessználatával helyezik a szembe, amely a következőket tartalmazza: (a) egy kanul, amelynek van egy külső fala, egy proxlmális vége. a proximálís végnek egy nyílása, egy disztáils ^ge, a diaztáiis végnek egy nyílása, és egy kimerne amely áthalad a kanülöm (b) egy okuláris Iniplantátum, amely olyan méretű és struktúrájú, hogy a szembe beültessék: és az okúiéba implantátum a lumenben helyezkedik el: és to) egy kupak, amelynek van egy zárt disztáiis vége és amely érintkezik a kanul külső íaláyal éi Mledl a kanul öisztáiis végét és a dísztálís vég nyílását, és a kupak á|y van kialakítva, hogy lehetővé tegye, hegy a kanht disztáíís vége és a iiaztáíls vég nyílása áthaladjon a kupakon^ amikor a kenuit hivezétik a szembe, fk Az 1. Igénypont szerinti használatra való prösztigfaridlrii áh# az említett prosztaglandin az (I) képiem vegyülni:
    ahol a szaggatott vonallal jelölt kötések egyes vagy kettős kötést képviselnek, amely lehet cisz vagy transz konfigurációban, A jelentése alkílén vagy alkenifén-gyök, amely kettő-hat szinatomot tartalmaz, amely gyököt egy vagy több oxidgyökkel lehet megszakítani és egy vagy több hídroxí, oxo. alklloxí vagy áikii-karboxi csoporttal lehet helyettesíteni, ahol az említett alkilgyök egy-hat szénatomot tartalmaz: a B egy cikloalkii gyök, amely három-hét szénatomot tartalmaz, vagy egy aril gyök, amelyet négy-tíz szénatomot tartalmazé hrdrokarbü árit és heieroari! gyökökből álló csoportból választanak ki, abet a heteroatomot a nitrogén-, oxigén- és kénatomokból álló csoportból választják ki; az X jelentése -(OR**), ahol az R4 csoportot egymástól függetlenül a hidrogénből és az egy-hat szénatommal rendelkező rövid széniénél? alkslgyőkből választják kl| A Z jelentése ~0. az R< és az R;· egyikének jelentése ~€λ -OH vagy egy -0(00)¾ csoport, a másik pedig -OH vagy -0(00)¾ vagy az Rí jelentése ~0 és az Rg feledése H; ahol az R.<: telített vagy telítetlen acikíikus szénhidrogén esppprt, amelynek szénaíamszlráf 1*P': 20*ig tarjad, vagy -(CHimlfc ahol mm érléke 0>ΊΙ* e^ R? jelentése clkloalkil gyök, amely háix?a>hit;iiii^alégic>l tartalmaz vagy Ndrokarbii-artl vagy heteroaril csoport, a Jirii meghatározás szerint. fi A 6. igénypont szerinti használatra való pmsztagtandín, ahol a pmsztagisndin a következő (II) képlettel répönilezlk,
    ahol az y értéke 0 vagy 1, x értéke 0 vagy 1 és x*y egyszerre nem lehet 1, Y a következőkből állő csoportból kiválasztott gyök: alkll, balogén. nltro; amjno, tíol. hldroxl, alkil-oxh aíkihkarboxl és halogénnel szubszikuált alkll. ahol az említett alkilgyök agy-hat szénatomot tartalmaz, n értéke 0 vagy 1 -tői 3-sg terjedő egész szám és Rá jelentése -O. -OH vagy ~~0(CÖ)R&amp;í ahol a vonalkázott vonalak az a If |i, i: IdlytenoS: ha rpmslőgekl pgőíg Iá; beta Vilify raolőt: jélő ük. E Az 7, Igénypont szerinti hasznliatra velő prnsztaglandín, ahol a prosztaglandln latanoprosztot, travopmsztot, ezek sélt vagy keverékeit tartalmazza, Jh A 8, Igénypont szerinti használatra véti pmszlaglandirk ahol az emlltért íiOP csökkenése a kiindulási értékhez képest legalább -60% m Az előző igénypontok bármelyike szerinti használatra való prosztaglandm, ahol az Implantátum átmérője kevesebb, mint 500 pm. it. Az 1-9. igénypontok bármelyik© szerinti haazpátetra vaiö presztsglandin, ahol az ímptentáUim úgy van mii'etazve, hogy Bfeizkediao a szom tridokomeátle szögé n ek a na tó m iéjá h oz.
HUE14194703A 2010-04-16 2011-04-14 Az intraokuláris nyomás csökkentése intrakamerális bimatoproszt implantátumokkal HUE033186T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/761,765 US8673341B2 (en) 2004-04-30 2010-04-16 Intraocular pressure reduction with intracameral bimatoprost implants

Publications (1)

Publication Number Publication Date
HUE033186T2 true HUE033186T2 (hu) 2017-11-28

Family

ID=44194969

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE14194703A HUE033186T2 (hu) 2010-04-16 2011-04-14 Az intraokuláris nyomás csökkentése intrakamerális bimatoproszt implantátumokkal
HUE16201104A HUE040529T2 (hu) 2010-04-16 2011-04-14 Intraokuláris nyomáscsökkentés intrakamerális prosztamid implantátumokkal

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16201104A HUE040529T2 (hu) 2010-04-16 2011-04-14 Intraokuláris nyomáscsökkentés intrakamerális prosztamid implantátumokkal

Country Status (21)

Country Link
US (3) US8673341B2 (hu)
EP (5) EP3456323A1 (hu)
JP (5) JP5982360B2 (hu)
KR (2) KR102252437B1 (hu)
CN (2) CN111450041A (hu)
AU (1) AU2011239642B2 (hu)
BR (1) BR112012026535A2 (hu)
CA (2) CA3010374A1 (hu)
CY (3) CY1115912T1 (hu)
DK (3) DK3205333T3 (hu)
ES (3) ES2707801T3 (hu)
HU (2) HUE033186T2 (hu)
IL (1) IL222457A (hu)
MX (1) MX2012012040A (hu)
PL (3) PL2558081T3 (hu)
PT (3) PT3205333T (hu)
RU (1) RU2586298C2 (hu)
SG (2) SG184905A1 (hu)
SI (3) SI2558081T1 (hu)
TR (1) TR201820663T4 (hu)
WO (1) WO2011130462A2 (hu)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
AU2002258754B2 (en) 2001-04-07 2006-08-17 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US7799336B2 (en) * 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US9498457B2 (en) * 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
CA2668954C (en) 2006-11-10 2020-09-08 Glaukos Corporation Uveoscleral shunt and methods for implanting same
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US20170360609A9 (en) 2007-09-24 2017-12-21 Ivantis, Inc. Methods and devices for increasing aqueous humor outflow
US8267882B2 (en) 2008-03-05 2012-09-18 Ivantis, Inc. Methods and apparatus for treating glaucoma
WO2010093945A2 (en) 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
WO2012071476A2 (en) 2010-11-24 2012-05-31 David Haffner Drug eluting ocular implant
CA2764063C (en) 2009-06-03 2019-05-14 Forsight Labs, Llc Anterior segment drug delivery
WO2011006113A1 (en) 2009-07-09 2011-01-13 Ivantis, Inc. Ocular implants and methods for delivering ocular implants into the eye
WO2011006078A1 (en) 2009-07-09 2011-01-13 Ivantis, Inc. Single operator device for delivering an ocular implant
KR20180117211A (ko) * 2010-01-22 2018-10-26 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
CA2798084A1 (en) 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
EP3967297A1 (en) 2011-04-29 2022-03-16 Allergan, Inc. Sustained release latanoprost implant
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US8657776B2 (en) 2011-06-14 2014-02-25 Ivantis, Inc. Ocular implants for delivery into the eye
CN106073986B (zh) 2011-09-14 2019-01-11 弗赛特影像5股份有限公司 治疗患者的眼睛的装置
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9554940B2 (en) 2012-03-26 2017-01-31 Glaukos Corporation System and method for delivering multiple ocular implants
US9358156B2 (en) 2012-04-18 2016-06-07 Invantis, Inc. Ocular implants for delivery into an anterior chamber of the eye
US20150272877A1 (en) * 2012-10-26 2015-10-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
WO2014066653A1 (en) * 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release intraocular drug delivery systems
WO2014066775A1 (en) 2012-10-26 2014-05-01 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
US10617558B2 (en) 2012-11-28 2020-04-14 Ivantis, Inc. Apparatus for delivering ocular implants into an anterior chamber of the eye
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
BR122019025507B1 (pt) * 2013-03-15 2021-01-12 Allergan, Inc. implante intraocular biodegradável contendo prostamida e seu uso
EP2978406A1 (en) * 2013-03-27 2016-02-03 Forsight Vision5, Inc. Bimatoprost ocular silicone inserts and methods of use thereof
US9504653B2 (en) 2013-04-01 2016-11-29 Allergan, Inc. Microsphere drug delivery system for sustained intraocular release
EP3669865A1 (en) 2013-10-31 2020-06-24 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
JP2016538050A (ja) * 2013-11-15 2016-12-08 グローコス コーポレーション 安定な薬物製剤を貯蔵及び放出するように構成された眼内インプラント
WO2015184173A1 (en) 2014-05-29 2015-12-03 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10709547B2 (en) 2014-07-14 2020-07-14 Ivantis, Inc. Ocular implant delivery system and method
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
US20210228408A1 (en) * 2015-07-23 2021-07-29 Allergan, Inc. Glaucoma Treatment Via Intracameral Ocular Implants
CN108135470B (zh) 2015-08-14 2021-03-09 伊万提斯公司 具有压力传感器和输送系统的眼部植入物
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
WO2017106517A1 (en) 2015-12-15 2017-06-22 Ivantis, Inc. Ocular implant and delivery system
CN109937025B (zh) 2016-04-20 2022-07-29 多斯医学公司 生物可吸收眼部药物的递送装置
CA3038075A1 (en) 2016-09-23 2018-03-29 Incept, Llc Intracameral drug delivery depots
USD841152S1 (en) 2017-06-27 2019-02-19 Monica S. Naylor Eye drop container
WO2019070385A2 (en) 2017-10-06 2019-04-11 Glaukos Corporation SYSTEMS AND METHODS FOR PLACING MULTIPLE OCULAR IMPLANTS
USD846738S1 (en) 2017-10-27 2019-04-23 Glaukos Corporation Implant delivery apparatus
CA3091154C (en) 2018-02-22 2023-10-03 Ivantis, Inc. Ocular implant and delivery system
CN112566622A (zh) * 2018-06-19 2021-03-26 细胞疗法有限责任公司 用于治疗青光眼或高眼压症的包含眼内压降低剂、cnp化合物、npr-b化合物、tie-2激动剂或神经营养剂的缓释药物递送系统
BR112021026265A2 (pt) 2019-06-27 2022-06-14 Layerbio Inc Métodos e sistemas de entrega de dispositivos oculares
AU2021215929A1 (en) 2020-02-06 2022-08-04 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases
US11540940B2 (en) 2021-01-11 2023-01-03 Alcon Inc. Systems and methods for viscoelastic delivery

Family Cites Families (205)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT252264B (de) 1965-03-17 1967-02-10 Etapharm Chem Pharm Lab Ges M Verfahren zur Herstellung eines reinen hochviskosen Hyaluronsäurepräparates
US3393081A (en) * 1966-12-06 1968-07-16 Monsanto Co Heat sealable moisture barrier coatings for polystyrene articles
US3749776A (en) 1970-08-28 1973-07-31 Allergan Pharma Method for blocking prostaglandin activity
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
SE390255B (sv) 1974-02-18 1976-12-13 N G Y Torphammar Upprullningsanordning foretredesvis for ett sekerhetsbelte i ett fordon
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US3966749A (en) 1975-02-10 1976-06-29 Interx Research Corporation Novel synthesis of optically active m-acyloxy-α-[(methylamino)methyl]benzyl alcohols, the pharmaceutically acceptable acid addition salts thereof and intermediate useful in the preparation thereof
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4052505A (en) 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4057619A (en) 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4063064A (en) 1976-02-23 1977-12-13 Coherent Radiation Apparatus for tracking moving workpiece by a laser beam
US4186184A (en) 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4190642A (en) 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4285957A (en) 1979-04-10 1981-08-25 Richardson-Merrell Inc. 1-Piperidine-alkanol derivatives, pharmaceutical compositions thereof, and method of use thereof
US4303637A (en) 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4281654A (en) 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4396625A (en) 1980-05-13 1983-08-02 Sumitomo Chemical Company, Limited Treatment of glaucoma or ocular hypertension and ophthalmic composition
US4425346A (en) 1980-08-01 1984-01-10 Smith And Nephew Associated Companies Limited Pharmaceutical compositions
US4304765A (en) 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
JPS58126435U (ja) 1982-02-19 1983-08-27 オリンパス光学工業株式会社 Ttlオ−トストロボ用絞り制御回路
US4454151A (en) 1982-03-22 1984-06-12 Syntex (U.S.A.) Inc. Use of pyrrolo pyrroles in treatment of ophthalmic diseases
US4599353A (en) 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (de) 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Mit Metallgriffen, insbesondere Edelstahlgriffen, versehenes Koch- und Bratgeschirr mit Deckel
US4649151A (en) 1982-09-27 1987-03-10 Health Research, Inc. Drugs comprising porphyrins
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
US4478818A (en) 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US6309669B1 (en) 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4675338A (en) 1984-07-18 1987-06-23 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4693885A (en) 1984-07-18 1987-09-15 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
FR2577509B1 (fr) 1985-02-21 1987-05-07 Nirvana Espar Systems Sa Mat de bateau a voile
US4656186A (en) 1985-04-30 1987-04-07 Nippon Petrochemicals Co., Ltd. Tetrapyrrole therapeutic agents
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
FR2594438B1 (fr) 1986-02-14 1990-01-26 Labaz Sanofi Nv Derives d'indolizine, leur procede de preparation ainsi que les compositions en contenant
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
CA1311686C (en) 1986-06-25 1992-12-22 John Weldon Shell Controlled release bioerodible drug delivery system
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5089509A (en) 1988-09-15 1992-02-18 Allergan, Inc. Disubstituted acetylenes bearing heteroaromatic and heterobicyclic groups having retinoid like activity
US4981871A (en) 1987-05-15 1991-01-01 Abelson Mark B Treatment of ocular hypertension with class I calcium channel blocking agents
DE3734223A1 (de) 1987-10-09 1989-04-20 Boehringer Ingelheim Kg Implantierbares, biologisch abbaubares wirkstofffreigabesystem
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4865846A (en) 1988-06-03 1989-09-12 Kaufman Herbert E Drug delivery system
US5190966A (en) 1988-07-06 1993-03-02 Health Research, Inc. Purified hematoporphyrin dimers and trimers useful in photodynamic therapy
US4968715A (en) 1988-07-06 1990-11-06 Health Research, Inc. Use of purified hematoporphyrin trimers in photodynamic therapy
US5198460A (en) 1988-07-20 1993-03-30 Health Research Inc. Pyropheophorbides and their use in photodynamic therapy
US5002962A (en) 1988-07-20 1991-03-26 Health Research, Inc. Photosensitizing agents
US5093349A (en) 1988-07-20 1992-03-03 Health Research Inc. Photosensitizing agents
ES2213504T1 (es) 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
US4935498A (en) 1989-03-06 1990-06-19 Board Of Regents, The University Of Texas System Expanded porphyrins: large porphyrin-like tripyrroledimethine-derived macrocycles
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5173504A (en) 1989-04-21 1992-12-22 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5171741A (en) 1989-04-21 1992-12-15 Health Research, Inc. Bacteriochlorophyll-a derivatives useful in photodynamic therapy
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US4932984A (en) 1989-07-27 1990-06-12 The Dow Chemical Company Process for reduction of chlorinated solvent emissions
US5268178A (en) 1989-09-25 1993-12-07 The Board Of Regents, The University Of Texas System Biodegradable antibiotic implants and methods of their use in treating and preventing infections
US5503721A (en) 1991-07-18 1996-04-02 Hri Research, Inc. Method for photoactivation
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5075115A (en) 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
US5232844A (en) 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5196460A (en) * 1990-05-29 1993-03-23 Repap Technologies Inc. Rubber compositions containing high purity lignin derivatives
US5100431A (en) 1990-09-27 1992-03-31 Allergan, Inc. Single stitch suture needle and method
KR0185215B1 (ko) 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
CA2055522A1 (en) 1990-12-12 1992-06-13 Masako Andoh Microspheres for ophthalmic use
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
JP3351525B2 (ja) 1991-06-21 2002-11-25 ジェネティックス・インスティテュート・インコーポレイテッド 骨形成性蛋白医薬処方物
US5356629A (en) 1991-07-12 1994-10-18 United States Surgical Corporation Composition for effecting bone repair
US5169638A (en) 1991-10-23 1992-12-08 E. R. Squibb & Sons, Inc. Buoyant controlled release powder formulation
US5543154A (en) 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
US5656297A (en) 1992-03-12 1997-08-12 Alkermes Controlled Therapeutics, Incorporated Modulated release from biocompatible polymers
US5384333A (en) 1992-03-17 1995-01-24 University Of Miami Biodegradable injectable drug delivery polymer
IT1263116B (it) 1992-04-09 1996-07-30 Rotta Research Lab Derivati basici dell'acido glutammico ed acido aspartico, procedimento per la loro preparazione e loro uso farmaceutico
US5655832A (en) 1992-04-16 1997-08-12 Tir Technologies, Inc. Multiple wavelength light processor
US5244914A (en) 1992-04-27 1993-09-14 American Cyanamid Company Stable porfimer sodium compositions and methods for their manufacture
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US6217869B1 (en) 1992-06-09 2001-04-17 Neorx Corporation Pretargeting methods and compounds
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5707643A (en) 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
WO1995003807A1 (en) 1993-07-27 1995-02-09 The University Of Sydney Treatment of age-related macular degeneration
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US5385887A (en) 1993-09-10 1995-01-31 Genetics Institute, Inc. Formulations for delivery of osteogenic proteins
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
DE4403326C1 (de) 1994-02-03 1995-06-22 Hans Reinhard Prof Dr Koch Intraokulare Linsenanordnung zur Astigmatismuskorrektur
US5798349A (en) 1994-03-14 1998-08-25 The General Hospital Corporation Use of green porphyrins to treat neovasculature in the eye
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6270492B1 (en) 1994-09-09 2001-08-07 Cardiofocus, Inc. Phototherapeutic apparatus with diffusive tip assembly
US5585401A (en) 1994-12-09 1996-12-17 The Reents Of The University Of California Method for enhancing outflow of aqueous humor in treatment of glaucoma
US5972326A (en) 1995-04-18 1999-10-26 Galin; Miles A. Controlled release of pharmaceuticals in the anterior chamber of the eye
US5612027A (en) 1995-04-18 1997-03-18 Galin; Miles A. Controlled release of miotic and mydriatic drugs in the anterior chamber
US5869079A (en) 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
HUP9700322A3 (en) 1995-06-09 2001-03-28 Euro Celtique Sa Formulations and methods for providing prolonged local anesthesia
US5906920A (en) 1995-08-29 1999-05-25 The Salk Institute For Biological Studies Methods for the detection of ligands for retinoid X receptors
US5958954A (en) 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US6066675A (en) 1996-09-13 2000-05-23 The Regents Of The University Of California Method for treatment of retinal diseases
US5913884A (en) 1996-09-19 1999-06-22 The General Hospital Corporation Inhibition of fibrosis by photodynamic therapy
US6270749B1 (en) 1996-12-11 2001-08-07 Pharmacyclics, Inc. Use of Texaphyrin in ocular diagnosis and therapy
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
EP0994709A4 (en) 1997-06-30 2006-02-01 Allergan Inc CALCIUM BLOCKER FOR THE TREATMENT OF PROLIFERATIVE VITREORETINOPATHY
CA2300154C (en) 1997-08-11 2008-07-08 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6306426B1 (en) 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
FR2767699A1 (fr) * 1997-08-28 1999-02-26 Oreal Composition filmogene epaissie
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US6646001B2 (en) 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6271220B1 (en) 1998-03-11 2001-08-07 Allergan Sales, Inc. Anti-angiogenic agents
DE69940738D1 (de) 1998-07-09 2009-05-28 Curelight Medical Ltd Vorrichtung und verfahren zur wirkungsvollen hochenergetischen photodynamischen therapie von akne vulgaris und seborrhoe
EP1131114B1 (en) 1998-11-20 2004-06-16 The University of Connecticut Apparatus and method for control of tissue/implant interactions
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6482854B1 (en) 1999-03-25 2002-11-19 Massachusetts Eye And Ear Infirmary Glaucoma treatment
US6290713B1 (en) 1999-08-24 2001-09-18 Thomas A. Russell Flexible illuminators for phototherapy
US6317616B1 (en) 1999-09-15 2001-11-13 Neil David Glossop Method and system to facilitate image guided surgery
AU768400B2 (en) 1999-10-21 2003-12-11 Alcon Inc. Drug delivery device
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6728918B1 (en) 1999-11-01 2004-04-27 Matsushita Electric Industrial Co., Ltd. Relay transmission method and system, and device used thereof
US6319273B1 (en) 1999-12-16 2001-11-20 Light Sciences Corporation Illuminating device for treating eye disease
US6395787B1 (en) 2000-02-08 2002-05-28 Allergan Sales, Inc. Ocular hypotensive lipids
CA2398901C (en) 2000-02-10 2010-11-16 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US20040208910A1 (en) 2000-04-26 2004-10-21 Control Delivery Systems, Inc. Sustained release device and method for ocular delivery of adrenergic agents
PE20020146A1 (es) 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
HUP0303197A3 (en) 2000-07-14 2008-03-28 Allergan Inc Compositions containing alpha-2 adrenergic agonist components
US6357568B1 (en) 2000-09-27 2002-03-19 Shou Mao Chen Structure for protecting a luggage shell
AU2002248284A1 (en) 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
US6595945B2 (en) 2001-01-09 2003-07-22 J. David Brown Glaucoma treatment device and method
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
EP1387671A1 (en) 2001-05-03 2004-02-11 MASSACHUSETTS EYE &amp; EAR INFIRMARY Implantable drug delivery device and use thereof
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
US6713268B2 (en) 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
US20030220376A1 (en) 2001-08-10 2003-11-27 Pharmacia Corporation Methods for treating carbonic anhydrase mediated disorders
US7749528B2 (en) 2001-08-29 2010-07-06 Ricardo Azevedo Pontes De Carvalho Implantable and sealable medical device for unidirectional delivery of therapeutic agents to tissues
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
AU2002341881B2 (en) 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US20040058313A1 (en) 2002-04-24 2004-03-25 Abreu Marcio Marc Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
AU2003217531A1 (en) 2002-05-02 2003-11-17 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
US20050245509A1 (en) 2002-08-29 2005-11-03 Santen Pharmacecutical Co., Ltd. Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
KR20050047118A (ko) * 2002-09-18 2005-05-19 알러간, 인코포레이티드 안과 임플란트의 수송을 위한 방법 및 장치
US6899717B2 (en) 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
AU2003295409B2 (en) 2002-11-06 2010-02-11 Durect Corporation Controlled release depot formulations
JP2004196787A (ja) 2002-12-04 2004-07-15 Santen Pharmaceut Co Ltd 結膜下デポによるドラッグデリバリーシステム
US20040137059A1 (en) 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20090148527A1 (en) 2007-12-07 2009-06-11 Robinson Michael R Intraocular formulation
US7186744B2 (en) 2003-11-13 2007-03-06 Allergan, Inc. Prostamides for the treatment of glaucoma and related diseases
JP2007520496A (ja) 2004-02-04 2007-07-26 レットメッド ピーティーワイ リミテッド 徐放性ステロイド組成物
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US20060182781A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244462A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
US20050244458A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244461A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US20050244478A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20050244465A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20050244466A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US20050244471A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
PL1856042T3 (pl) 2005-03-10 2012-11-30 Allergan Inc Podstawione gamma laktamy jako środki terapeutyczne
US7585895B2 (en) 2005-12-06 2009-09-08 Allergan, Inc. Therapeutic substituted cyclopentanes
US7427685B2 (en) 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
CN101330914A (zh) 2005-12-16 2008-12-24 爱尔康公司 使用alk5调节剂控制眼内压
ES2653845T3 (es) 2006-01-17 2018-02-09 Novartis Ag Dispositivo de tratamiento de administración de fármaco
AU2007212271B2 (en) * 2006-02-09 2012-11-01 Santen Pharmaceutical Co., Ltd. Stable formulations, and methods of their preparation and use
US7592364B2 (en) 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US9039761B2 (en) 2006-08-04 2015-05-26 Allergan, Inc. Ocular implant delivery assemblies with distal caps
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8846073B2 (en) * 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US7589213B2 (en) 2007-04-27 2009-09-15 Old David W Therapeutic substituted lactams
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US7947732B2 (en) 2007-07-13 2011-05-24 Allergan, Inc. Therapeutic substituted chlorocyclopentanols
US7740604B2 (en) 2007-09-24 2010-06-22 Ivantis, Inc. Ocular implants for placement in schlemm's canal
IL186598A0 (en) 2007-10-11 2008-11-03 Mohammad Abdulrazik Composition and method for the treatment or prevention of glaucoma and ocular hypertension
CN102977048A (zh) 2007-11-09 2013-03-20 阿勒根公司 具有前列腺素活性的取代环戊烷
PL2291368T3 (pl) 2008-04-24 2013-05-31 Allergan Inc Podstawione gama laktamy jako środki terapeutyczne
EP2296621A1 (en) 2008-05-20 2011-03-23 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20100098772A1 (en) 2008-10-21 2010-04-22 Allergan, Inc. Drug delivery systems and methods for treating neovascularization
US20100104654A1 (en) 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
WO2010093945A2 (en) * 2009-02-13 2010-08-19 Glaukos Corporation Uveoscleral drug delivery implant and methods for implanting the same
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
KR20180117211A (ko) 2010-01-22 2018-10-26 알러간, 인코포레이티드 전방내 서방성 치료제 이식물
US20130071349A1 (en) 2010-03-02 2013-03-21 Allergan, Inc. Biodegradable polymers for lowering intraocular pressure

Also Published As

Publication number Publication date
US20240277609A1 (en) 2024-08-22
AU2011239642B2 (en) 2016-11-03
EP3205333B1 (en) 2018-10-03
EP3456323A1 (en) 2019-03-20
CA3010374A1 (en) 2011-10-20
US20140316009A1 (en) 2014-10-23
PT2902018T (pt) 2017-03-03
CN103002884B (zh) 2020-01-07
CN111450041A (zh) 2020-07-28
DK2902018T3 (en) 2017-03-06
JP2020114430A (ja) 2020-07-30
JP6683787B2 (ja) 2020-04-22
DK2558081T3 (en) 2015-03-02
JP2013525302A (ja) 2013-06-20
WO2011130462A2 (en) 2011-10-20
ES2528117T3 (es) 2015-02-04
RU2586298C2 (ru) 2016-06-10
BR112012026535A2 (pt) 2016-07-12
DK3205333T3 (en) 2019-01-21
CY1120299T1 (el) 2019-07-10
JP2019014736A (ja) 2019-01-31
US8673341B2 (en) 2014-03-18
JP6946503B2 (ja) 2021-10-06
WO2011130462A3 (en) 2012-05-10
MX2012012040A (es) 2013-02-07
CY1121064T1 (el) 2019-12-11
CA2796443A1 (en) 2011-10-20
ES2617285T3 (es) 2017-06-16
CA2796443C (en) 2018-08-21
EP3205333A1 (en) 2017-08-16
KR20180117718A (ko) 2018-10-29
CN103002884A (zh) 2013-03-27
SI2558081T1 (sl) 2015-04-30
CY1115912T1 (el) 2017-01-25
TR201820663T4 (tr) 2019-02-21
KR20130064740A (ko) 2013-06-18
AU2011239642A1 (en) 2012-11-08
JP2016166242A (ja) 2016-09-15
IL222457A0 (en) 2012-12-31
JP6416154B2 (ja) 2018-10-31
PT2558081E (pt) 2015-02-05
EP4316594A3 (en) 2024-05-15
EP2558081A2 (en) 2013-02-20
US20100278898A1 (en) 2010-11-04
JP5982360B2 (ja) 2016-08-31
HUE040529T2 (hu) 2019-03-28
EP4316594A2 (en) 2024-02-07
IL222457A (en) 2017-10-31
PL3205333T3 (pl) 2019-03-29
PL2902018T3 (pl) 2017-07-31
JP2022000441A (ja) 2022-01-04
SI3205333T1 (sl) 2019-03-29
ES2707801T3 (es) 2019-04-05
EP2902018A1 (en) 2015-08-05
PT3205333T (pt) 2019-01-11
SG10201606415UA (en) 2016-09-29
SG184905A1 (en) 2012-11-29
KR102252437B1 (ko) 2021-05-14
SI2902018T1 (sl) 2017-07-31
EP2558081B1 (en) 2015-01-07
KR101915326B1 (ko) 2018-11-05
PL2558081T3 (pl) 2015-06-30
EP2902018B1 (en) 2016-11-30
RU2012147550A (ru) 2014-05-27

Similar Documents

Publication Publication Date Title
US20240277609A1 (en) Intraocular pressure reduction with intracameral bimatoprost implants
KR102126007B1 (ko) 전방내 서방성 치료제 이식물
KR20160077121A (ko) 프로스타마이드-함유 안구내 삽입물 및 그것의 사용 방법
US20240130890A1 (en) Sustained-release implants for lowering intraocular pressure with extended duration of effect
US20230026451A1 (en) Intraocular pressure reduction with intracameral bimatoprost implants